Shield Therapeutics is a high potential, commercial stage specialty-pharma company. We pride ourselves on providing solutions to unmet medical needs and delivering value to our shareholders.
Shield has a rare opportunity to build an integrated, highly profitable specialty pharma business. In this section you can learn more about our lead product, and about our second asset.
Shield is well positioned to become a fast growing, independent, international specialty pharmaceutical company due to the strength of its products and team, and with great thanks to all of our supportive shareholders.
As a unified team we are constantly driven by and committed to our goals, seeking to deliver them with transparency and respect. Being consistent to this vision, while enjoying the journey, has brought us to where we are today.
Stay up to date with the exciting new developments as we continue to grow.
Shield Therapeutics plc, today announces its unaudited interim results for the six months ended 30 June 2018. For further details please see the attachment provided…
Shield Therapeutics plc, today announces completion of recruitment of the AEGIS–H2H Phase 3b study of oral Feraccru compared to Intravenous (IV) ferric carboxymaltose in subjects…
London, UK, 26 July 2018: Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs, with…
Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs, with an initial focus on addressing…
Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients’ unmet medical needs, today reports on recent presentations of…
STX_PK Paediatric Study_Final_14June18
For further details please see the press release below: STX_RNS Board Change
STX_RNS AGM NOTICE
Shield Therapeutics plc (LSE:STX) today announces its preliminary Group results for the year ended 31 December 2017. For full details view the press release here.
